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Moyé and Tita basically address two issues. First, in their
view, one-sided testing should be avoided in health care re-
search, especially in randomized trials, and is typically mo-




 intuition or suggestive
information from prior studies, or “belief.” Second, they ar-
gue that “the two-sided test shines bright, direct light on the
possible production of harm by the intervention,” especially
unsuspected harm. On both issues we do not agree with
their views.
Both the one-sided and two-sided approach presuppose a
good balance between uncertainty (otherwise the trial would
not be necessary) and plausibility (otherwise the trial would
not be justified) of a relevant hypothesis based on clinical
and scientific insights. One-sided testing is appropriate and
even indicated if such testing is sufficient to answer the cen-
tral research question. This is the case if (1) the scientific
hypothesis to be tested is obviously one sided, or if (2) only
a clear advantage in effect of the principal over the refer-
ence intervention would have consequences for practice, for
instance, if the principal intervention implies a more bur-
densome regimen for the patient. An example of (1) would
be an exploratory trial comparing a new intervention with a
placebo. Only a clear benefit for the new intervention will
make further research indicated. No difference, or superior-
ity of the placebo, would lead to the end of research on this
new intervention. This “one-sided” scientific hypothesis of
a possible relevant effect, not “a strong belief in the benefit
of a therapy,” is to be confirmed or rejected. Such an hy-
pothesis is relevant irrespective of individual beliefs, al-
though a very strong (dis)belief of investigators would be a
contraindication to perform the trial. Regarding (2), we can-
not understand why investigators should prove that a princi-
pal intervention is worse than a reference intervention, in-
stead of “not better,” if applying the principal intervention
in clinical practice would only be acceptable if it were
clearly more effective.
We emphasize again, that the price of not sharing our
view is high in terms of subjects to be included and clinical
end points needed. Elaborating our numerical examples in
the original Commentary, we get the picture of Table 1.
Looking at the situation with the higher incidence (50% in
the reference group) in the two-sided option, not only 166
more subjects must be included in the trial, but the expected
total number of “end points” would be 349 before it could
be decided that the principal treatment is better, not better,
or worse as to the primary end points. In the one-sided op-
tion, the expected number of end points would be 275 be-
fore it could be decided that the principal treatment is better
or not better. Especially if the end points would be severe
morbidity or death, which is often the case, the difference of
74 is huge. In the example with the lower incidence (10% in
the reference group), the corresponding differences are
smaller but still relevant. So, the price for two-sided testing
is so high that it would be only acceptable if a convincing
reason is given. In other words, we advocate one-sided test-
ing as the default option: “one-sided, unless . . .” instead of
“two sided, unless . . .”
The sample size of an effectiveness trial is neither explic-
itly estimated nor generally appropriate to detect unsus-
pected harm. We already argued that for both practical and
scientific purposes it is often not necessary to establish the
statistical significance of inferiority of the principal inter-
vention. As far as unsuspected adverse events are con-
cerned, these can typically not be taken as the basis for sam-
ple size estimation. Moreover, trials will almost never have
sufficient power to detect very low rates of severe adverse
effects that could be clinically relevant. Detecting unsus-
pected adverse effects would require enormous sample sizes
that will still never be large enough to detect them all. In ad-
dition, the approach advocated by Moyé and Tita might er-
 
Table 1
Required numbers per comparison group and expected numbers of primary end points (smoothed to absolute numbers) to detect a minimal cumulative 
incidence reduction of 10%, starting from one- and two-sided testing, respectively, for expected cumulative incidences of 20% and 50% in the reference group 










to be detected Group size and number of endpoints One-sided testing Two-sided testing
reference group: 20% Required group size 157 199
principal group: 10% Primary endpoints
reference group 31 40




reference group: 50% Required group size 305 388
principal group: 40% Primary endpoints
reference group 153 194




Source: Knottnerus JA, Bouter LM, Ned Tijdschr Geneeskd 2001;145:1051–4.
 




roneously suggest that the principal intervention is safe
when, in the context of an effectiveness study, a two-sided
approach has not demonstrated clinically relevant adverse
effects. However, one should not mix up studies aimed to
study effectiveness as to primary clinical end points (which
may also include adverse effects to be intentionally evalu-
ated, for example when looking at the incidence of both
stroke and bleeding in a warfarin trial) with studies espe-
cially designed to detect or exclude infrequent but severe,
and unsuspected adverse effects. The latter type of studies,
either experimental or observational, have specific require-
ments, regarding both methodology and sample size estima-
tion [1]. Of course, it is wise to use infrequent adverse ef-
fects earlier observed in effectiveness trials in preparing
such studies. Also, we must always be keen to take action
after observing unsuspected frequent adverse effects in ef-
fectiveness trials. For such situations an independent and
thoughtful case-by-case judgement on the necessity of im-
mediate action or further evaluation is important, rather than
the idea that a default two-sided approach would have
avoided further study.
If a one-sided trial shows no benefit (but possible harm),
repetition is not necessary after such a trial, because the
study question (in this case, whether the principal treatment
would be better) has already been answered. Trials should
be focused on specific questions. It would be ethically dis-
putable to collect more events than needed for answering
the specific question participants were invited for, with the
motivation that detection of harm among these participants
might be useful in view of additional, possibly future, indi-
cations. Other indications should be studied as such, with a
tailor-made specific design.
Indeed, if feasible, stopping rules can prevent unneces-
sary (and thus unethical) allocation to inferior interventions.
But the possibility to apply stopping rules is not at all the
monopoly of the two-sided approach. Such rules can also be
implemented according to a one-sided approach both re-
garding primary endpoints and adverse effects. [2–4]. In
general, however, we must keep in mind that the feasibility
of stopping rules depends on a combination of slow recruit-
ment and a short follow-up to the primary end point.
For us, “complexity” of two-sided testing nor “simplic-
ity” of one-sided testing, nor any relation between complex-
ity and ethics, is at stake in choosing between a one- or two-
sided approach. We just say: in many effectiveness trials, to
choose a one-sided approach is appropriate. In their study
design, researchers should explicitly describe why the one-
or two-sided approach is their starting point for sample size
estimation. If an investigator thinks that more subjects
should be included or more “end points” are needed before
a conclusion in a clinical trial can be reached, in the context
of a two-sided instead of a one-sided approach, this should
be positively motivated and critically reviewed in advance.
In summary, we believe that the one-sided approach
should be the default option.
J. André Knottnerus
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